Justin K. Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Justin K. Huang has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Christopher A. Bristow
20 shared publicationsGiulio F. Draetta
20 shared publications- Ningping Feng
Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas
20 shared publications Akira Inoue
15 shared publications- Alessandro Carugo
Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
15 shared publications Andrea Viale
15 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 Legend from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 Legend from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 Legend from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 Legend from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1-9 from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1-9 from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1-9 from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1-9 from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
Computational prediction of binding between neoantigen peptides and major histocompatibility complex (MHC) proteins can be used to predict patient response to cancer immunotherapy. Current neoantigen predictors focus on in silico estimation of MHC binding affinity and are limited by low predictive value for actual peptide presentation, inadequate support for rare MHC alleles, and poor scalability to high-throughput data sets. To address these limitations, we developed MHCnuggets, a deep neural network method that predicts peptide–MHC binding. MHCnuggets can predict binding for common or rare alleles of MHC class I or II with a single neural network architecture. Using a long short-term memory network (LSTM), MHCnuggets accepts peptides of variable length and is faster than other methods. When compared with methods that integrate binding affinity and MHC-bound peptide (HLAp) data from mass spectrometry, MHCnuggets yields a 4-fold increase in positive predictive value on independent HLAp data. We applied MHCnuggets to 26 cancer types in The Cancer Genome Atlas, processing 26.3 million allele–peptide comparisons in under 2.3 hours, yielding 101,326 unique predicted immunogenic missense mutations (IMM). Predicted IMM hotspots occurred in 38 genes, including 24 driver genes. Predicted IMM load was significantly associated with increased immune cell infiltration (P < 2 × 10−16), including CD8+ T cells. Only 0.16% of predicted IMMs were observed in more than 2 patients, with 61.7% of these derived from driver mutations. Thus, we describe a method for neoantigen prediction and its performance characteristics and demonstrate its utility in data sets representing multiple human cancers.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
Computational prediction of binding between neoantigen peptides and major histocompatibility complex (MHC) proteins can be used to predict patient response to cancer immunotherapy. Current neoantigen predictors focus on in silico estimation of MHC binding affinity and are limited by low predictive value for actual peptide presentation, inadequate support for rare MHC alleles, and poor scalability to high-throughput data sets. To address these limitations, we developed MHCnuggets, a deep neural network method that predicts peptide–MHC binding. MHCnuggets can predict binding for common or rare alleles of MHC class I or II with a single neural network architecture. Using a long short-term memory network (LSTM), MHCnuggets accepts peptides of variable length and is faster than other methods. When compared with methods that integrate binding affinity and MHC-bound peptide (HLAp) data from mass spectrometry, MHCnuggets yields a 4-fold increase in positive predictive value on independent HLAp data. We applied MHCnuggets to 26 cancer types in The Cancer Genome Atlas, processing 26.3 million allele–peptide comparisons in under 2.3 hours, yielding 101,326 unique predicted immunogenic missense mutations (IMM). Predicted IMM hotspots occurred in 38 genes, including 24 driver genes. Predicted IMM load was significantly associated with increased immune cell infiltration (P < 2 × 10−16), including CD8+ T cells. Only 0.16% of predicted IMMs were observed in more than 2 patients, with 61.7% of these derived from driver mutations. Thus, we describe a method for neoantigen prediction and its performance characteristics and demonstrate its utility in data sets representing multiple human cancers.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress
Supplementary Figure 2. Knocking out ARID1A does not impair viability in PDAC cell lines.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress
Supplementary Figure 2. Knocking out ARID1A does not impair viability in PDAC cell lines.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Legends from Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress
Legends of Supplementary Figures and Tables
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Legends from Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress
Legends of Supplementary Figures and Tables
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress
Supplementary Figure 1. Characterization of 23 PDAC cell lines.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress
Supplementary Figure 1. Characterization of 23 PDAC cell lines.